Generate Bio drops as data accidentally leaked ahead of European conference
Generate Bio drops as data accidentally leaked ahead of European conference
Generate Biomedicines
NASDAQ: GENB $15.72 USD
Generate Biomedicines, Inc. (NASDAQ: GENB) is a clinical-stage generative-biology company headquartered in Somerville, Massachusetts, using machine learning and its Generate Platform to program novel protein therapeutics; it went public in February 2026 and is a Flagship Pioneering-founded company whose lead programs span immunology (GB-0895 anti-TSLP) and oncology (GB-4362, GB-5267).
Company Info
Sector:AI / Machine Learning
Headquarters:Somerville, Massachusetts, USA
Founded:2018
Website:www.generatebiomedicines.com/
Clinical Development Pipeline
GB-0895
Target: Long-acting anti-TSLP monoclonal antibody (every-six-month dosing)GB-4362
Target: MMAE payload neutralizerGB-5267
Target: MUC16 CAR-T cell therapyRecent News
Leadership Team
Michael T. Nally
CEO and Director
Dr. Noubar B. Afeyan, PhD
Co-Founder and Independent Chair of the Board
Dr. Jason E. Silvers, JD, MD
President and CFO
Dr. Gevorg Grigoryan, PhD
Co-Founder and CTO